Case against Celgene over Thalomid, Revlimid should go forward, buyers argue
MLex Summary: A court should hear claims that drugmaker Celgene abused safety regulations and used sham patent litigation to prevent generic competitors from making versions of the costly drugs Thalomid and...To view the full article, register now.
Already a subscriber? Click here to view full article